Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ...
NEWTON, Mass.--(BUSINESS WIRE)--Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative, non-systemic, oral protein therapeutics to treat metabolic and orphan diseases, today ...
Business Wire (press release) - Wed, 10 Feb 2016 04:00



Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2015 Results ...
Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals Conference Call to discuss Fourth Quarter and Year End 2015 Financial Results. There will be a question-and-answer session to follow. Please be advised that this ...
Seeking Alpha - Thu, 11 Feb 2016 19:00

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial ...
Business Wire (press release) - Thu, 11 Feb 2016 13:00

Recent Broker Updates On Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)
Its current development programs include Dacryocystorhinostomy (DCR)-PH1 for Primary Hyperoxaluria Type 1 (PH1), Additional Liver Targets, DCR-MYC for MYC-related cancers and KRAS Program. Dicerna's discovery approach is based on ...
Risers & Fallers - Thu, 11 Feb 2016 05:21



Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced it has initiated dosing in the first clinical trial of DCR-PH1, ...
Business Wire (press release) - Mon, 21 Dec 2015 13:00

Dicerna Pharma (DRNA) Initiates Dosing in Phase 1 Study of DCR-PH1
StreetInsider.com - Mon, 21 Dec 2015 13:00

Dicerna Files IND Application for Primary Hyperoxaluria Drug
shares were up almost 7.0% immediately after the company announced that it has submitted an Investigational New Drug (IND) application to the FDA for DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1). However, most of the gains were lost ...
Nasdaq - Fri, 04 Sep 2015 11:45

Alnylam Provides Update on RNAi Therapeutics Pipeline
Alnylam also plans to initiate a number of phase I studies on its candidates, including ALN-GO1 (primary hyperoxaluria type 1), ALN-TTRsc02 (all forms of ATTR amyloidosis) and ALN-HBV (chronic hepatitis B viral infection). Alnylam currently carries a ...
Zacks.com - Wed, 13 Jan 2016 12:26

Zacks: Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Receives Consensus Rating of ...
Its current development programs include Dacryocystorhinostomy (DCR)-PH1 for Primary Hyperoxaluria Type 1 (PH1), Additional Liver Targets, DCR-MYC for MYC-related cancers and KRAS Program. Dicerna's discovery approach is based on ...
IRA Market Report - Mon, 01 Feb 2016 09:37

Alnylam Pharma Initiated with Outperform, $154 PT at Credit Suisse – Shares ...
Its product development programs also include ALN-AS1 for the treatment of hepatic porphyrias; ALN-AAT for the treatment of alpha-1 antitrypsin deficiency liver disease; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-TMP for the ...
WallStreet.org - Wed, 20 Jan 2016 11:07


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014